 |
Wuhan Nutra Biotechnology Co., Ltd.ISRIB ,Cosmetic Peptide, Tideglusib ,Way316606,Nootropics |
    
   
|
|||
Contact Us
E-mail: catherine@nutrabiotechchem.com
Roxadustat FG-4592 CAS 808118-40-3
Product Description:
FG-4592
CAS：808118-40-3
MF：C19H16N2O5
MW：352.34
EINECS 813-400-2
Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD).[2][3] It is taken by mouth.
The most common side effects include hypertension (high blood pressure), vascular access thrombosis (formation of blood clots in the blood vessels associated with dialysis), diarrhea, peripheral edema (swelling especially of the ankles and feet), hyperkalemia (high blood potassium levels) and nausea (feeling sick).
Roxadustat received its first global approval in China on 17 December 2018,or the treatment of anemia caused by CKD in patients who are dialysis-dependent.[5] It was approved in Japan in 2019, for the treatment of anemia caused by CKD in patients on dialysis, and in 2020 for patients not on dialysis.[6] Roxadustat was approved for medical use in the European Union in August 2021
CAS：808118-40-3
MF：C19H16N2O5
MW：352.34
EINECS 813-400-2
Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD).[2][3] It is taken by mouth.
The most common side effects include hypertension (high blood pressure), vascular access thrombosis (formation of blood clots in the blood vessels associated with dialysis), diarrhea, peripheral edema (swelling especially of the ankles and feet), hyperkalemia (high blood potassium levels) and nausea (feeling sick).
Roxadustat received its first global approval in China on 17 December 2018,or the treatment of anemia caused by CKD in patients who are dialysis-dependent.[5] It was approved in Japan in 2019, for the treatment of anemia caused by CKD in patients on dialysis, and in 2020 for patients not on dialysis.[6] Roxadustat was approved for medical use in the European Union in August 2021
Links:
Copyright © Wuhan Nutra Biotechnology Co., Ltd. All right reserved
